SenzaGen is a Lund-based biotech company that develops and sells in-vitro (non-animal) testing methods for allergy and toxicology assessment. Its proprietary GARD platform uses genomic biomarkers to determine whether chemicals cause skin sensitization, replacing traditional animal testing. Listed on Nasdaq First North, SenzaGen has 37 employees, reported SEK 58 million in revenue for 2025, and expanded its GLP-certified laboratory in Lund to increase capacity in line with its 2030 Growth Plan.
senzagen.comPart of: Skåne Startup map